|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300075581 |
|
最近更新日期: Date of Last Refreshed on: |
2023-09-08 15:21:41 |
|
注册时间: Date of Registration: |
2023-09-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
危重症获得性虚弱可视化+评价体系构建临床研究 |
|
Public title: |
Study on the construction of visualization evaluation system for acquired weakness in critical illness |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
危重症获得性虚弱可视化+评价体系构建临床研究 |
|
Scientific title: |
Study on the construction of visualization evaluation system for acquired weakness in critical illness |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周沫 |
研究负责人: |
尹万红 |
|
Applicant: |
MO ZHOU |
Study leader: |
WANHONG YIN |
|
申请注册联系人电话: Applicant telephone: |
+86 187 1530 9637 |
研究负责人电话: Study leader's telephone: |
+86 135 1810 6758 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
179319164@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
yinwanhong@wchscu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
Study leader's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023年审(1422)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee on Biomedical Research, West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-09-01 00:00:00 |
||
|
伦理委员会联系人: |
邓绍林 |
||
|
Contact Name of the ethic committee: |
Shaolin Deng |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号老八教412-413室 |
||
|
Contact Address of the ethic committee: |
Room 412-413, the 8th Old Teaching Building,37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 2654 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
none |
||||||||||||||||||||||
|
Target disease: |
acquired weakness in critical illness |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过人群分层和危险因素权重分层的队列研究,明确不同危重症虚弱发生的核心风险因素以及风险权重,建立预测模型,进而为临床针对性干预提供依据,也为以后的基础科研设定不同的虚弱模型深入研究提供方向。建立危重症患者不同虚弱表型(以四肢无力为主,以呼吸肌功能障碍为主,以吞咽障碍为主等),明确不同表型虚弱发生的核心风险因素以及风险权重,建立预测模型。随访危重症患者远期生存、生活质量、自理能力、认知功能,明确风险因素对远期预后的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
Through a cohort study of population stratification and risk factor weight stratification, the core risk factors and risk weights for the occurrence of frailty in different critically ill patients were identified, and predictive models were established to provide a basis for clinical targeted interventions and provide direction for future in-depth research on different frailty models. Establish different frailty phenotypes in critically ill patients (mainly limb weakness, respiratory muscle dysfunction, swallowing disorders, etc.), clarify the core risk factors and risk weights for the occurrence of frailty in different phenotypes, and establish a predictive model. Follow up on long-term survival, quality of life, self-care ability, and cognitive function of critically ill patients, and clarify the impact of risk factors on long-term prognosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、年龄>18 岁 2、预估患者住院时间>3 天 3、愿接受本次实验并签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age>18 years old 2. Estimated patient hospitalization time>3 days 3. Willing to accept this experiment and sign an informed consent form |
||||||||||||||||||||||
|
排除标准: |
1、无法获取肌肉脂肪超声图像患者; 2、临床资料不完整的患者; 3、有原发运动功能障碍或明确的神经肌肉疾病; 4、腰椎、骨盆、下肢创伤或手术; 5、四肢缺陷; 6、双下肢测量点出现红肿、出血等情况; 7、预期死亡或进行姑息治疗 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients who are unable to obtain ultrasound images of muscle fat; 2. Patients with incomplete clinical data; 3. Having primary motor dysfunction or clear neuromuscular diseases; 4. Lumbar spine, pelvis, lower limb trauma or surgery; 5. Limb defects; 6. Redness, swelling, bleeding, etc. at the measurement points of both lower limbs; 7. Expect death or seek palliative treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-08-28 00:00:00至 To 2026-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-08-28 00:00:00 至 To 2026-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF以及电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
use both CRF and EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |